MYM Nutraceuticals Inc.

Developing High-Quality CBD Nutraceuticals for the Global Marijuana Market

This profile is part of a paid investor education campaign.*


MYM Nutraceuticals Inc. (CSE:MYM) is an emerging cannabis grower and nutraceuticals manufacturing and distribution company focused on Canadian and Australian medical marijuana markets. The company’s aggressive strategy for success is based on a commitment to superior growing technology, well-crafted branding and innovative distribution strategies.

This strategy coupled with strategic partners and sales revenue from multiple brands places MYM Nutraceuticals squarely on the path to becoming a fully-integrated cannabis company.

Through its subsidiary, Sublime Culture Inc., MYM Nutraceuticals is in the last stages of obtaining License Producer status under Health Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR), and anticipates completing the first harvest at its Quebec-based operation by the end of 2017.

Over the course of 2017, MYM has expanded its operations in both Quebec, Canada and Australia. In Quebec, the company is in the first phase of construction for a 36,000-square-foot facility in Laval and in the design phase of a 1.5 million-square-foot greenhouse facility in Weedon. In Australia, MYM has partnered with PUF Ventures Inc (CSE:PUF) on the development of a 1.2 million-square-foot cultivation facility in the northern region of New South Wales.

MYM Nutraceuticals’ is in active discussions related to further acquisitions of complimentary businesses and assets in the technology, nutraceuticals and CBD sectors to build a strong presence within the cannabis industry. The company is led by an experienced management team with a track record of successful startups and expertise in navigating emerging markets. The Quebec-based cannabis production team has more than 30 years of growing experience and the skills to produce high-quality cannabis products.

Company Highlights

  • Phase 1 of Laval facility to be completed in Q1 2018.
  • In design phase for 1.5 million-square-foot facility in Weedon, Quebec
  • Partnered with PUF Ventures for build of 1.2 million-square-foot facility in New South Wales, Australia
  • Established medical client base with access to 3,000 patients
  • Strategic Partnerships with TheraCann Canada; Mohawk indigenous communities.
  • Building strong brand recognition and robust network of global distribution channels.
  • Raised $13 million in financing in 12 months ending January 2018.
  • Solid management team with more than over 40 years of medical marijuana experience that is unmatched in the industry.

Quebec Production Facilities

Sublime Culture is the production wing of MYM Nutraceuticals and is a late-stage applicant to Health Canada’s ACMPR with a 10,000-square foot grow facility located in near Montreal in the city of Laval, Quebec. At build out, the facility is expected to produce approximately 3,000 kilograms of cannabis flower, generating an estimate annual revenue of $25 million.

Phase 2 of development expansion will include a roof-top greenhouse and a state-of-the-art extraction and processing department. The company intends to produce high-quality CBD products as well as Indica and Sativa cannabis strains for its patient-clients.

MYM’s subsidiary, CannaCanada Inc, has also partnered with the City of Weedon, in Quebec on the Weedon project, which will see the construction of a 1.5 million-square-foot greenhouse facility. Expected to be one of the largest production facilities in the world, the greenhouse has been approved by the municipal government and a license application is pending with Health Canada. 

To date, the engineering land studies for the property have been completed and the project is progressing through its Health Canada application. The processing, packaging and distribution plant design has been completed and the final implementation on the greenhouse design for the first phase of 300,000 square feet is on track. By full capacity in 2020, the company expects to produce up to 150,000 kilograms of cannabis per year.

“MYM is working to open up cannabis distribution channels globally to accelerate our growth,” said MYM CEO Rob Gietl. “Our Weedon project alone has 329 acres to expand production on. As recreational cannabis opens in more markets and as global markets expand, we plan on being ahead of the curve and have supply chains ready.” The company recently acquired an additional 18% of CannaCanada and the Weedon, Quebec project bringing the company’s total ownership of the late stage ACMPR applicant up to 93%.

MYM Australia

Expanding their international reach, MYM has also entered into a partnership with Solaris Nutraceuticals Inc. for the construction of a 1.2 million square-foot greenhouse facility in New South Wales, Australia. The project, named Northern Rivers, is a partnership with the Richmond Valley Council and will see the construction of a large-scale, manufacturing, processing and office facilities focused on cultivation, production and manufacturing of medical cannabis. MYM owns 35 percent of the project and the company plans to cover 300,000 square feet in the first phase of construction. At full scale, the facility will have the capacity to support annual production of 100,000 kilograms of high-quality cannabis.

Solaris Nutraceuticals Inc. has recently applied to the Australian Office of Drug Control for a medical cannabis license and a cannabis research license in collaboration with the National Institute of Complimentary Medicine (NICM). The company plans to conduct medical research at their Australian cultivation facility.

Processes and Brands

Establishing the “Gold Standard” in Quality Assurance Testing of Cannabis Products

Government health agencies are tightening regulations in terms of consistency and potency in cannabis products; and prescribing healthcare specialists need assurance of the safety and efficacy of the medical cannabis products they are prescribing. Health Canada announced in February 2017 that the agency “will begin conducting random testing of medical cannabis products by licensed producers” to ensure Canadian medical cannabis consumers “are receiving safe, quality-controlled product.”

MYM Nutraceuticals is dedicated to first-in-class R&D in developing the highest quality cannabis-based nutraceuticals. The company’s planned extraction and processing department will also house a cannabis product testing and research laboratory in partnership with TheraCann Canada. Along with its ISO 17025(2005)- compliance services, TheraCann is also providing MYM with TheraCannSYSTEM software to directly capture all testing and analysis data for more streamlined regulatory compliance and preparations for future Health Canada audits.

“MYM is looking to build the industry standard in all-inclusive cannabis facilities to meet the demands of the Canadian consumer. With the anticipated start of recreational legalization coming online in the summer of 2018, MYM will be positioned to provide the safest products in the market,” said Rob Gietl, CEO


Rob Gietl— CEO

Rob Gietl is well known for his ability to exponentially grow businesses including the west-coast franchise expansion of Domino’s Pizza, where he consistently grew the annual business to achieve 300+% increases year-over-year. Mr. Gietl is a seasoned Business Development and Operations executive with a diverse track record of leading change across all areas of concept creation, brand re-positioning, market penetration, fiscal accountability and efficient execution of business plans. He has grown business effectiveness in an array of sectors and circumstances throughout Canada, consistently aligned with stakeholders’ goals and values.

Erick Factor—Executive Chairman

Erick Factor is a well-known expert in the MMJ industry and has 20 years of experience in cultivating medical marijuana and manufacturing cannabis by-products, and has provided medical marijuana to thousands of patients over the past two decades. He has extensive experience working with Health Canada, from whom he has obtained MMAR and MMPR licenses for hundreds of patients, and has managed and operated grow facilities to produce for those patients. Mr. Factor has also gained invaluable experience over the past three years in ACMPR licensing regulations and applications.

Ian Ramage —Director

Ian Ramage holds a B.A.Sc. in Computer Engineering from Simon Fraser University and J.D. and LL.M. degrees from the University of British Columbia. He practiced law in the Bay Area for eight years for a variety of biotech and high-tech clients before returning to Vancouver in 2009 to continue to build his corporate and securities practice. Mr. Ramage is an expert in Canadian and U.S securities and corporate law; copyright and trademark acquisition and enforcement; patent, copyright, and trade secret litigation.

Mark Forster —CFO

Mark Forster will be responsible for the preparation of financial statements, continuing disclosure of the Resulting Issuer and the management of internal control procedures. He has over 25 years of financial accounting experience in banking, manufacturing of beer, wine, and spirits, the oil and gas industry and in the mining sector. He has been a director and the CFO of Teletouch Services Inc., a private technology company, since December 2004. He was a manager of Bearingpoint LLP, a management and technology company, from January 1996 to December 2006. Mark G. Forster was granted a CGA designation by the Certified General Accountant’s Association, BC in 1992.

*Disclaimer: The profile provides information which was sourced and approved by MYM Nutraceuticals Inc. in order to help investors learn more about the company. MYM Nutraceuticals Inc. is a client of the Investing News Network (INN). The company’s campaign fees pay for INN to create and update this profile page, to which links are placed on and channel newsletters.
The company description, investment highlights and catalysts were sourced by INN and approved by the company. INN does not guarantee the accuracy or thoroughness of the information contained on this page.
INN does not provide investment advice and the information on profile should not be considered a recommendation to buy or sell any security.
INN does not endorse or recommend the business, products, services or securities of any company profiled.
Readers should conduct their own research for all information publicly available concerning the company.